| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0166-0934(99)00135-4 |
| P698 | PubMed publication ID | 10644089 |
| P2093 | author name string | J L Miller | |
| D C Lee | |||
| R Rubenstein | |||
| K Cai | |||
| K J Gilligan | |||
| C J Stenland | |||
| E K Ford | |||
| M Fournel | |||
| R C Hartwell | |||
| S R Petteway | |||
| P2860 | cites work | Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins | Q24564014 |
| Prions | Q24633319 | ||
| Mice devoid of PrP are resistant to scrapie | Q28249108 | ||
| Novel proteinaceous infectious particles cause scrapie | Q29547678 | ||
| Eight prion strains have PrP(Sc) molecules with different conformations | Q29617277 | ||
| A new variant of Creutzfeldt-Jakob disease in the UK. | Q34374893 | ||
| Purified prion proteins and scrapie infectivity copartition into liposomes | Q34630806 | ||
| Separation and properties of cellular and scrapie prion proteins | Q35598678 | ||
| Creutzfeldt-Jakob disease in mice: persistent viremia and preferential replication of virus in low-density lymphocytes. | Q37109122 | ||
| Genetic and infectious prion diseases | Q40713552 | ||
| Inactivation of SE agents | Q40729971 | ||
| Viremia in Experimental Creutzfeldt-Jakob Disease | Q40894348 | ||
| Subcellular distribution and physicochemical properties of scrapie-associated precursor protein and relationship with scrapie agent | Q44409884 | ||
| Combination ultrafiltration and 6 M urea treatment of human growth hormone effectively minimizes risk from potential Creutzfeldt-Jakob disease virus contamination | Q44755682 | ||
| Infectivity and host responses in Creutzfeldt-Jakob disease | Q45036589 | ||
| Purification of the scrapie agent by density gradient centrifugation | Q45130367 | ||
| Rapid detection of Creutzfeldt-Jakob disease and scrapie prion proteins | Q46079042 | ||
| Preclinical detection of PrPSc in nictitating membrane lymphoid tissue of sheep | Q48013348 | ||
| The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy | Q48395317 | ||
| Molecular characteristics of the major scrapie prion protein | Q48591056 | ||
| A protease-resistant protein is a structural component of the scrapie prion | Q48720663 | ||
| Sensitive enzyme-linked immunosorbent assay for detection of PrP(Sc) in crude tissue extracts from scrapie-affected mice | Q48787485 | ||
| Scrapie infectivity and prion protein are distributed in the same pH range in agarose isoelectric focusing | Q49058272 | ||
| Immunodiagnosis of prion disease. | Q52197639 | ||
| Concentration and distribution of infectivity and PrPSc following partial denaturation of a mouse-adapted and a hamster-adapted scrapie strain. | Q52220560 | ||
| The genomic identity of different strains of mouse scrapie is expressed in hamsters and preserved on reisolation in mice | Q69226275 | ||
| Sustained viremia in experimental hamster scrapie. Brief report | Q70504979 | ||
| Reduction of the infectivity of scrapie agent as a model for BSE in the manufacturing process of Trasylol | Q71721256 | ||
| Improvement of PrPSc-detection in mouse spleen early at the preclinical stage of scrapie with collagenase-completed tissue homogenization and Sarkosyl-NaCl extraction of PrPSc | Q71783447 | ||
| Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein | Q71970964 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 77-89 | |
| P577 | publication date | 2000-01-01 | |
| P1433 | published in | Journal of Virological Methods | Q15749961 |
| P1476 | title | Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein | |
| P478 | volume | 84 |
| Q44045156 | A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies |
| Q36630654 | Absolute quantification of prion protein (90-231) using stable isotope-labeled chymotryptic peptide standards in a LC-MRM AQUA workflow |
| Q34755539 | Advances in pretransfusion infectious disease testing: ensuring the safety of transfusion therapy |
| Q34685468 | Blood infectivity in transmissible spongiform encephalopathies |
| Q51771677 | Capacity of the manufacturing process of Flebogamma® DIF, a new human high purity intravenous immunoglobulin, to remove a TSE model-agent |
| Q34535212 | Critical factors influencing prion inactivation by sodium hydroxide |
| Q48297400 | Current strategies to prevent transmission of prions by human plasma derivatives |
| Q36354421 | Diagnostic approaches for viruses and prions in stem cell banks |
| Q47947331 | Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII. |
| Q36088165 | Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens |
| Q37625927 | Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer |
| Q36529095 | Fuzheng Huayu Recipe Ameliorates Liver Fibrosis by Restoring Balance between Epithelial-to-Mesenchymal Transition and Mesenchymal-to-Epithelial Transition in Hepatic Stellate Cells |
| Q37415409 | Human tonsil-derived follicular dendritic-like cells are refractory to human prion infection in vitro and traffic disease-associated prion protein to lysosomes |
| Q48187181 | Investigation of PrPres in dental tissues in variant CJD. |
| Q46729499 | Mass spectrometric detection of attomole amounts of the prion protein by nanoLC/MS/MS. |
| Q36192013 | Microbiological control in stem cell banks: approaches to standardisation |
| Q34688199 | Molecular diagnostics of transmissible spongiform encephalopathies |
| Q31122708 | Multistrip Western blotting to increase quantitative data output |
| Q74238042 | New assays for measuring prions reassure FDA |
| Q51633844 | Novel methods for disinfection of prion-contaminated medical devices. |
| Q48451773 | Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma |
| Q37737558 | Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid |
| Q35083260 | Peripheral tissue involvement in sporadic, iatrogenic, and variant Creutzfeldt-Jakob disease: an immunohistochemical, quantitative, and biochemical study |
| Q51787809 | Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment. |
| Q48770230 | Rapid diagnosis of human prion disease using streptomycin with tonsil and brain tissues. |
| Q28546205 | Removal of transmissible spongiform encephalopathy prion from large volumes of cell culture media supplemented with fetal bovine serum by using hollow fiber anion-exchange membrane chromatography |
| Q45873610 | Safety procedures of coagulation factors |
| Q41777610 | Separation of native prion protein (PrP) glycoforms by copper-binding using immobilized metal affinity chromatography (IMAC) |
| Q48164724 | Sodium hydroxide renders the prion protein PrPSc sensitive to proteinase K |
| Q43992119 | Solvent-dependent precipitation of prion protein |
| Q36196688 | Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases |
| Q37139733 | Sucrose-formulated octocog alfa: a review of its use in patients with haemophilia A. |
| Q40595731 | The impact of variant CJD on transfusion practices in the UK. |
| Q34410655 | The prion protein protease sensitivity, stability and seeding activity in variably protease sensitive prionopathy brain tissue suggests molecular overlaps with sporadic Creutzfeldt-Jakob disease |
| Q38324712 | The standard scrapie cell assay: development, utility and prospects |
| Q57092938 | Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay |
| Q34624297 | Validation of biopharmaceutical purification processes for virus clearance evaluation |
| Q34236649 | Widespread PrPSc accumulation in muscles of hamsters orally infected with scrapie |
Search more.